Study of Sac-TMT for advanced ovarian cancer without HRD
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV ovarian cancer (or primary peritoneal or fallopian tube cancer) that is high-grade serous, high-grade endometrioid, clear cell, or certain mixed types.
- You had surgery to remove as much of the tumor as possible (debulking surgery) before or after chemo.
- You completed one round of platinum-based chemotherapy (like carboplatin or cisplatin) and it helped or kept the cancer stable.
- Your tumor is not HRD-positive (meaning it doesn't have a specific gene change that makes it more likely to respond to other treatments).
- You do not have active infections that need treatment, a history of severe eye disease, or uncontrolled heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a new drug called Sac-TMT for people with advanced squamous cell carcinoma of the vagina or vulva that has spread or cannot be cured with standard treatments. The drug targets a protein on cancer cells to deliver chemotherapy directly to the tumor, potentially slowing or stopping its growth.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This clinical trial tests a combination of two drugs—Sac-TMT (an antibody-drug conjugate that targets tumor cells) and bevacizumab (a drug that blocks blood vessel growth to tumors)—as a second-line treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if this combination can help people whose cancer has progressed after initial chemotherapy and immunotherapy.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.